Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.

The natural history of prostate cancer is highly variable and difficult to predict accurately. Better markers are needed to guide management and avoid unnecessary treatment. In this study, we validate the prognostic value of a cell cycle progression score (CCP score) independently and in a prespecified linear combination with standard clinical variables, that is, a clinical-cell-cycle-risk (CCR) score.

Paraffin sections from 761 men with clinically localized prostate cancer diagnosed by needle biopsy and managed conservatively in the United Kingdom, mostly between 2000 and 2003. The primary end point was prostate cancer death. Clinical variables consisted of centrally reviewed Gleason score, baseline PSA level, age, clinical stage, and extent of disease; these were combined into a single predefined risk assessment (CAPRA) score. Full data were available for 585 men who formed a fully independent validation cohort.

In univariate analysis, the CCP score hazard ratio was 2. 08 (95% CI (1. 76, 2. 46), P<10(-13)) for one unit change of the score. In multivariate analysis including CAPRA, the CCP score hazard ratio was 1. 76 (95% CI (1. 44, 2. 14), P<10(-6)). The predefined CCR score was highly predictive, hazard ratio 2. 17 (95% CI (1. 83, 2. 57), χ(2)=89. 0, P<10(-20)) and captured virtually all available prognostic information.

The CCP score provides significant pretreatment prognostic information that cannot be provided by clinical variables and is useful for determining which patients can be safely managed conservatively, avoiding radical treatment.

British journal of cancer. 2015 Jun 23 [Epub]

J Cuzick, S Stone, G Fisher, Z H Yang, B V North, D M Berney, L Beltran, D Greenberg, H Møller, J E Reid, A Gutin, J S Lanchbury, M Brawer, P Scardino

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. , Myriad Genetics, Inc. , Salt Lake City, UT, USA. , Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. , Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. , Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. , Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. , Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. , National Cancer Registration Service (Eastern Office), Public Health England, Cambridge, UK. , Cancer Epidemiology and Population Health, King's College London, London, UK. , Myriad Genetics, Inc. , Salt Lake City, UT, USA. , Myriad Genetics, Inc. , Salt Lake City, UT, USA. , Myriad Genetics, Inc. , Salt Lake City, UT, USA. , Myriad Genetics, Inc. , Salt Lake City, UT, USA. , Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

PubMed     Full Text Article